[THE EFFECT OF CYTOFLAVIN ON PARAMETERS OF THE LEFT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION.]
The effect of cytoflavin on parameters of the left ventricular systolic function (LVSF) during acute myocardial infarction was studied in a group of 46 patients which received this drug (in addition to standard therapy) intravenously as 20 mL of Polysan solution (St. Petersburg, Russia) diluted in 250 mL of 5% glucose solution once a day 30 min before coronary artery recanalization. The control group of 60 patients received only standard therapy. The drug effectiveness was evaluated in terms of LVSF parameters including the ejection fraction, end-diastolic volume, and end-systolic volume. The introduction of cytoflavin to pati- ents led to (i) increase in the ejection fraction of left ventricle by 7.9% as compared to patients of the control group and (ii) decrease in the end-diastolic and end-systolic volume of the left ventricle on 7th day of hospitalization by 10.6% and 17.9%, respectively (p < 0.05). The addition of cytoflavin to standard the- rapy significantly reduced the level of troponin I on the 7th day in patients with acute myocardial infarction down to 81% relative to the control and the activity of creatine kinase by 35% (p < 0.05). The inclusion of cytoflavin in the treatment of patients with acute myocardial infarction should be considered as pathoge- netically proved, clinically justified, and promising therapy.